Please Wait
Applying Filters...

Annual Sales of DSSTox_CID_3388 reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 939Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Zyprexa

PharmaCompass

01

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed

02

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed

03

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed

04

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed

05

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed

Brand Name : Zyprexa

arrow
AAPS 2024
Not Confirmed

Olanzapine

Main Therapeutic Indication : Neuroscience and Mental Health

Currency : USD

2015 Revenue in Millions : 1,037

2014 Revenue in Millions : 940

Growth (%) : -9%

blank

06

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed

07

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed

Brand Name : Zyprexa

arrow
AAPS 2024
Not Confirmed

Olanzapine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2016 Revenue in Millions : 725

2015 Revenue in Millions : 940

Growth (%) : -23

blank

08

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed

Brand Name : Zyprexa

arrow
AAPS 2024
Not Confirmed

Olanzapine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 581

2016 Revenue in Millions : 725

Growth (%) : -20

blank

09

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed

Brand Name : Zyprexa

arrow
AAPS 2024
Not Confirmed

Olanzapine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 471

2017 Revenue in Millions : 581

Growth (%) : -19%

blank

10

Brand Name : Zyprexa

Olanzapine

arrow
AAPS 2024
Not Confirmed